Creative Touch Permanent Makeup and Aesthetics

Type 2 diabetes mellitus (T2DM) is a chronic metabolic condition characterised by insulin resistance, progressive beta cell dysfunction, and sustained hyperglycaemia – the clinical endpoint of a deterioration that typically begins one to two decades earlier with insulin resistance, compensatory hyperinsulinaemia, and eventual beta cell exhaustion. It is not a binary switch but a continuum: the same pathophysiological mechanisms that define frank T2DM are already active at the prediabetes stage, and in many cases at normal fasting glucose levels with abnormal postprandial dynamics. The upstream drivers – habitual high-glycaemic dietary patterns, leptin resistance, hypothalamic inflammation, UPF-driven gut dysbiosis, and chronic low-grade inflammageing – are covered in their respective entities; this entity covers their convergence into clinical disease, the incretin defect that connects T2DM directly to the GLP-1 pharmacology cluster, the skin consequences that are among the most visible manifestations of the condition, and the evidence that T2DM remission is achievable through dietary intervention in a proportion of patients. At Creative Touch, T2DM and insulin resistance are clinically relevant not only as metabolic conditions but as determinants of skin architecture and treatment responsiveness that are frequently present, frequently undiagnosed, and frequently unaddressed in aesthetics practice.

Type 2 diabetes mellitus has historically been framed as a progressive, irreversible disease requiring escalating pharmacological management. That framing is now substantially challenged by evidence that remission is achievable in a meaningful proportion of patients through dietary intervention – a shift with important implications for how the condition is understood mechanistically, not just clinically. Understanding T2DM as the downstream consequence of reversible metabolic dysfunction, rather than an inevitable endpoint, changes the clinical conversation entirely.

Pathophysiology: Beyond Insulin Resistance

The standard narrative – insulin resistance leads to beta cell failure leads to T2DM – is accurate but incomplete. Ralph DeFronzo’s “ominous octet” framework, now well-established in the endocrinology literature, identifies eight distinct pathophysiological defects that converge in T2DM: ^[2]

• Impaired insulin secretion from pancreatic beta cells – both first-phase (the rapid initial spike) and second-phase (sustained) insulin responses are attenuated, with first-phase loss occurring early in the disease trajectory
• Insulin resistance in skeletal muscle – the primary site of postprandial glucose disposal; impaired GLUT4 translocation means glucose remains in circulation longer after each meal
• Increased hepatic glucose production – insulin normally suppresses overnight hepatic gluconeogenesis; in T2DM this suppression fails, producing fasting hyperglycaemia independently of dietary intake
• Increased glucagon secretion from pancreatic alpha cells – glucagon should fall post-meal; in T2DM it remains elevated, compounding hepatic glucose output at the wrong time
• Impaired incretin effect – covered separately below; the GLP-1 and GIP response to meals is blunted, removing the primary hormonal brake on postprandial glucose excursions
• Increased lipolysis from insulin-resistant adipose tissue – elevated circulating free fatty acids contribute to the lipotoxicity mechanism of insulin resistance in muscle and liver
• Increased renal glucose reabsorption via SGLT2 – the kidney, which would normally excrete excess glucose once a threshold is exceeded, has an upregulated reabsorption threshold in T2DM, retaining glucose that would otherwise be cleared; the mechanism that SGLT2 inhibitor medications target therapeutically
• Hypothalamic insulin resistance – central insulin signalling regulates both glucose homeostasis and appetite; its impairment contributes to both the metabolic and appetite-regulatory dimensions of the condition

Beta cell failure is not simply the endpoint of prolonged insulin overwork. Current evidence suggests that beta cell mass loss begins early – driven by glucotoxicity (chronic high glucose damaging beta cells directly), lipotoxicity ( fatty acid intermediates inducing endoplasmic reticulum stress and apoptosis), and beta cell senescence (accumulation of SASP-secreting senescent islet cells that impair remaining beta cell function through paracrine inflammation). The beta cell is being actively damaged by the same inflammatory and metabolic environment it is trying to compensate for. ^[1]

Metabolic Inflexibility and the Randle Cycle

A clinically underappreciated feature of T2DM is metabolic inflexibility – the loss of the cell’s normal capacity to switch efficiently between glucose and fatty acid oxidation depending on substrate availability. In the metabolically healthy state, cells shift to fat oxidation during fasting and back to glucose oxidation post-meal, with insulin as the primary switching signal. This substrate competition – the Randle cycle, described by Sir Philip Randle in 1963 – is a normal feature of metabolic regulation; the problem in T2DM is that the switching mechanism is impaired. en.wikipedia

Chronic hyperinsulinaemia and insulin resistance prevent clean metabolic switching: cells remain poorly responsive to insulin’s signal to engage glucose oxidation, whilst the chronic glucose excess elevates malonyl-CoA, inhibiting CPT-1 and preventing efficient fatty acid entry into the mitochondria. The result is a cell that cannot efficiently oxidise either fuel – generating mitochondrial dysfunction, reactive oxygen species, and the accumulation of diacylglycerol and ceramide intermediates that drive IRS-1 serine phosphorylation and further compound insulin resistance. The dietary relevance is direct: the fat-sugar combination characteristic of UPFs is specifically suited to sustaining this metabolically inflexible state, delivering both substrates simultaneously whilst enabling clean switching to neither. A diet that eliminates rapidly absorbed carbohydrate – allowing the cell to establish efficient fat oxidation – is the dietary mechanism by which low-carbohydrate interventions restore metabolic flexibility and improve insulin sensitivity, independent of weight loss. ^[3]

The Incretin Defect: The GLP-1 Bridge

One of the most important – and most therapeutically relevant – features of T2DM pathophysiology is the incretin defect. In metabolically healthy individuals, oral glucose ingestion produces substantially more insulin secretion than equivalent intravenous glucose – the difference attributable to the incretin hormones GLP-1 and GIP, released from the gut in response to nutrient contact. This incretin effect accounts for approximately 50–70% of postprandial insulin secretion in healthy individuals. ^[5]

academic.oup.com Despite similar absolute GIP and GLP-1 secretion across groups, the GIP/GLP-1 secretion ratio declined progressively as glucose tolerance deteriorated – and in hierarchical regression analysis, this ratio was the only significant predictor of first-phase beta cell function (rate sensitivity), explaining 30% of variance independently of BMI, renal function, and insulin sensitivity. The finding suggests that the imbalance in relative incretin dynamics – rather than absolute hormone secretion – may represent an early marker of beta cell dysfunction and chronic incretin resistance, preceding the secretory deficits that become measurable later in disease progression. The study is small and cross-sectional, limiting generalisability; the mechanistic insight it offers is nonetheless consistent with the broader incretin dysfunction literature and warrants attention as the field develops.

The therapeutic implication is the mechanistic basis for GLP-1 receptor agonist medications: by delivering sustained pharmacological GLP-1R activation that bypasses both the attenuated endogenous incretin response and the beta cell’s progressive insensitivity to it, GLP-1 RAs restore insulin secretion and suppress glucagon at the level the diseased incretin axis can no longer provide. This is not simply augmenting a normal system – it is replacing a specific defective component with a pharmacological substitute. The full GLP-1 mechanism is covered in the GLP-1 entity; the incretin defect is the bridge between T2DM pathophysiology and the GLP-1 pharmacology cluster.

Upstream Drivers: The Metabolic Continuum

T2DM does not arise in isolation. The upstream pathway from dietary pattern to clinical diagnosis typically spans years to decades and passes through recognisable intermediate states – each covered in their respective entity – that converge on beta cell exhaustion:

Dietary pattern → glycaemic load → postprandial glucose excursions: Habitual high-sugar and UPF intake delivers rapidly absorbed carbohydrate to the proximal intestine, bypassing ileal brake activation, generating repeated high-amplitude glucose spikes and compensatory insulin surges. The dietary upstream is developed in the High Sugar and UPF Intake entity.

Sustained hyperinsulinaemia → insulin resistance: Chronic insulin elevation downregulates insulin receptor expression and post-receptor signalling in muscle and liver. The lipotoxicity pathway – UPF-delivered fat-sugar combinations generating diacylglycerol and ceramide intermediates – compounds this through IRS-1 serine phosphorylation independently of insulin level.

Adipose inflammation → TNF-α/ IL-6 → insulin resistance: Expanding adipose tissue secretes TNF-α and IL-6 that directly impair insulin signalling in peripheral tissues. This is the shared mechanism between obesity, inflammageing, and T2DM – the same NF-κB-driven cytokine environment that accelerates biological ageing also degrades insulin sensitivity.

Leptin resistance → impaired appetite regulation: Leptin resistance, driven by hypothalamic inflammation from circulating LPS and saturated fatty acids, removes the adiposity brake on appetite and energy expenditure, promoting further fat accumulation and compounding insulin resistance. The mechanism is covered in the Leptin entity.

Beta cell senescence → SASP → local islet inflammation: Glucotoxicity and lipotoxicity drive beta cells into senescence; their SASP promotes local inflammation that damages remaining beta cell mass – a self-reinforcing deterioration loop connecting the Cellular Senescence entity directly to T2DM progression.

Skin Manifestations: The Visible Consequence

The skin consequences of T2DM are among its most visible and directly aesthetics-relevant features, yet they are frequently attributed to chronological ageing rather than metabolic disease. The mechanisms are distinct from normal ageing even when the surface presentation is similar.

Collagen fragmentation and MMP/TIMP disruption: High glucose directly upregulates MMP-1, MMP-2, and MMP-9 in human dermal fibroblasts (HDFs) – the cells responsible for collagen synthesis and matrix homeostasis in the dermis. The ratio of MMP-2/TIMP-2 and MMP-9/TIMP-1 increases in high-glucose conditions both in vitro (HDF cell culture) and in vivo (diabetic mouse models), producing a collagen homeostasis environment shifted decisively towards degradation over synthesis. Atomic force microscopy of diabetic skin shows fragmented, disorganised collagen fibrils with altered mechanical properties – increased cross-linking from AGE accumulation alongside structural fragmentation from MMP excess, producing a paradox of stiff but structurally compromised dermis. ^[6]

Reduced procollagen synthesis: Human dermal fibroblasts from diabetic donors show reduced secretion of procollagen Type I C- Peptide (PICP) – a direct marker of new collagen production – compared to non-diabetic donors. The reactive aldehyde methylglyoxal (MGO), a byproduct of glucose metabolism elevated in hyperglycaemia, is sufficient alone to reduce PICP secretion and induce the MIF-mediated inflammatory signalling characteristic of diabetic wound healing impairment. ^[7]

AGE accumulation in dermal matrix: The Maillard reaction between circulating glucose and the amino groups of long-lived dermal proteins produces AGEs that cross-link collagen and elastin fibrils, impairing their normal turnover and mechanical properties. Skin AGE levels measured by skin autofluorescence (SAF) correlate positively with skin stiffness in T2DM patients, confirming that the glycation burden is directly altering biomechanical skin properties. A 2025 review in Frontiers in Medicine confirmed elastin fibre fragmentation alongside collagen changes in diabetic skin – impairing elasticity and regenerative capacity simultaneously. ^[4]

Wound healing impairment: The combination of reduced collagen synthesis, MMP/TIMP imbalance, impaired fibroblast migration, and microvascular dysfunction produces the clinically significant wound healing impairment characteristic of T2DM. In an aesthetics context, this translates to slower and less predictable recovery from procedures that create controlled tissue injury – microneedling, RF microneedling, laser treatments, PRP protocols.

Epidermal thinning and barrier compromise: Reduced keratinocyte proliferation under hyperglycaemic conditions and AGE-driven changes to the dermal-epidermal junction produce epidermal thinning and compromised barrier function – increasing transepidermal water loss, reducing the skin’s tolerance to topical actives, and increasing susceptibility to post-procedure irritation and infection.

Remission: T2DM as a Reversible State

The traditional clinical framing of T2DM as a progressive, irreversible disease requiring lifelong escalating pharmacotherapy is not supported by current evidence. Remission – defined as sustained HbA1c below 48 mmol/mol without glucose-lowering medication – is achievable and has been demonstrated across multiple study designs. bmj

A BMJ systematic review and meta-analysis of RCTs found that low and very low carbohydrate diets achieved T2DM remission in 57% of participants at six months, compared to 31% in control conditions – the largest remission signal of any dietary intervention studied. The mechanism is direct: reducing dietary carbohydrate reduces postprandial glucose excursions, reduces the compensatory insulin demand on already-compromised beta cells, allows metabolic flexibility to be partially restored, and – through associated weight loss – reduces adipose-derived TNF-α/IL-6 that is impairing insulin signalling. bmj

The most compelling UK primary care evidence comes from Dr David Unwin’s 8-year audit of Norwood Surgery’s low-carbohydrate programme. Of the 186 patients who adopted the low-carbohydrate approach (39% of the practice T2DM register), 51% achieved T2DM remission and 20% of the practice’s entire T2DM population achieved drug-free remission. Mean HbA1c fell from 63 to 46 mmol/mol; mean triglycerides fell by 0.9 mmol/L; mean systolic blood pressure fell by 12 mmHg. Drug expenditure on diabetes medications ran at £4.94 per patient per year compared to £11.30 for local practices – a 56% reduction. These are not RCT results, but as an 8-year real-world audit in a UK primary care setting, they represent the most directly applicable evidence for how low-carbohydrate intervention performs in practice. nutrition.bmj

An important caveat applies to GLP-1 RA-mediated remission: the cardiometabolic improvements achieved during GLP-1 RA treatment – including improved glycaemic control – reverse upon cessation if dietary pattern is not simultaneously addressed. Pharmacological incretin replacement does not restore the endogenous satiety architecture or metabolic flexibility that dietary change addresses; remission that depends solely on continued medication is not remission in the meaningful sense. This is the same mechanistic argument developed in the GLP-1 Medication Discontinuation entity.